Clinical Lab Infrastructure
Security, Deployment, and Scale

For a traditional clinical chemistry lab, infrastructure means analyzers, reagent management, and a LIMS. For a clinical genomics lab, the scope is significantly larger.

• Compute resources: servers or cloud instances that run alignment, variant calling, and tertiary analysis pipelines.
• Storage systems: the architecture for storing raw sequencing data (FASTQ, BAM), variant calls (VCF), annotations, and clinical reports.
• Bioinformatics pipelines: validated, version-controlled software workflows that transform raw data into clinical results.
• Data management systems: variant knowledgebases, LIMS integrations, EHR connectivity.
• Security controls: access management, encryption, audit logging, network architecture.
• Compliance framework: the policies, procedures, and technical controls required for CAP/CLIA accreditation and HIPAA compliance.

Unlike general lab infrastructure, genomics infrastructure is data-intensive in ways that have no precedent in clinical chemistry. A single WGS run produces 100 to 200 GB of raw data. A lab running 50 genomes per week generates more than 500 TB of data per year, and that data must be stored, secured, and remain retrievable for years under clinical retention policies.

The most consequential infrastructure decision a genomics lab makes is where its data lives and who controls it. Three primary deployment models exist, each with distinct trade-offs across security, scalability, cost, and regulatory compliance.

Clinical genomics labs in the United States operate under a specific regulatory framework that shapes nearly every infrastructure decision. Understanding what each regulation actually requires (not just what it is) is essential for building a compliant infrastructure from the start.

CLIA: federal floor for US clinical labs

The Clinical Laboratory Improvement Amendments of 1988 establish federal standards for all laboratory testing performed on human specimens in the US. For NGS-based labs, CLIA compliance means: all analytical procedures must be validated before clinical use, personnel must meet competency requirements, quality control must be documented, proficiency testing must be completed for applicable analytes, and records must be retained for defined periods (typically 2 years for test records, longer for certain genomic reports). CLIA is enforced through CMS, often via inspection by accreditation organizations such as CAP, which has deemed status to inspect on CMS's behalf.

From an infrastructure standpoint, CLIA compliance requires that your bioinformatics pipeline is analytically validated: you have documented evidence of its sensitivity, specificity, precision, and reproducible performance for each variant type and assay. A pipeline that produces different results on the same input files on different days is not CLIA-compliant.

ISO 15189: international counterpart

ISO 15189 is an international standard for medical laboratory quality and competence. Voluntary in most jurisdictions (including the US) but may be required by international health authorities or institutional contracts. The international equivalent of CAP accreditation, recognized across Europe, Asia, and other regions. For genomics labs operating internationally, pursuing both CAP (which satisfies CLIA) and ISO 15189 provides the broadest recognition. Golden Helix operates under an ISO 13485-certified quality management system (the device-industry equivalent) which provides the documentation, change control, and audit trail practices that support both CAP and ISO 15189 inspections.

HIPAA and genomic data

HIPAA classifies genomic sequence data from identified or identifiable individuals as protected health information (PHI). Direct implications for every infrastructure layer:

• At rest: all PHI (FASTQ, BAM, VCF, clinical reports) encrypted at rest. AES-256 is the standard.
• In transit: data between systems (sequencer to server, server to LIMS, server to EHR) encrypted in transit with TLS 1.2 or higher.
• Access controls: minimum-necessary access for authorized personnel. Role-based access control with individual accounts and MFA. Shared credentials are not acceptable.
• Audit logging: all PHI access logged. Logs retained and reviewable. Login events, file access, report generation, data export.
• Business Associate Agreements: any vendor that processes, stores, or transmits PHI on your behalf must sign a BAA. Cloud providers, LIMS vendors, clinical software vendors.

GDPR for international genomics programs

For labs handling genomic data from EU residents (including US-based labs receiving samples from EU patients), GDPR applies. Genomic data is classified as a "special category" of personal data, subject to the strictest protections. Key infrastructure implications: data residency (EU genomic data generally must remain in the EU or be transferred only to countries with adequate data protection, a complex and evolving area post-Schrems II), data minimization, right to erasure (your infrastructure must support patient deletion requests), and breach notification within 72 hours of becoming aware. For programs serving both US and EU patients, cloud deployment with EU-region data isolation, or a separate EU on-premises instance, is typically the most practical compliance architecture.

Healthcare organizations are the most targeted sector for cyberattacks globally, and clinical genomics labs face a specific version of this threat: genomic data is uniquely sensitive because, unlike a stolen credit card number, a patient's genome cannot be changed once exposed.

The threat landscape

• Ransomware is the most operationally disruptive threat. Clinical labs are attractive targets because downtime directly affects patient care, creating pressure to pay. The 2020 Universal Health Services attack cost an estimated $67M and disrupted hundreds of hospitals. On-prem and air-gapped systems with offline backups are most resilient.
• Phishing and social engineering target lab personnel to obtain credentials. A single compromised account with PHI access is a reportable HIPAA breach. Security awareness training is a required administrative safeguard.
• Insider threats (malicious or accidental) are the most common source of healthcare data breaches. Access controls, audit logging, and least-privilege principles directly mitigate this.
• Supply chain attacks target software vendors and update mechanisms. A compromised update can deliver malware into an otherwise well-secured environment. A strong argument for working with vendors under formal quality management systems with controlled release processes.

Minimum security controls

The following are not optional for a CAP/CLIA-compliant clinical genomics infrastructure.

The bioinformatics pipeline is the engine of a clinical genomics lab and the component most often underestimated in infrastructure planning. A pipeline that works for 10 samples per week breaks down at 100. A pipeline built for research fails CLIA validation because it is not deterministic.

What makes a clinical pipeline different from a research pipeline

Compute requirements

Rough benchmarks for a well-optimized pipeline, per sample.

These are per-sample. A lab running 20 WES cases per day needs enough compute to process those within the clinical TAT window, which typically means parallel processing across multiple nodes, not sequential processing on a single server.

Storage tiers

• Hot storage (active analysis): fast NVMe or SSD for samples actively being processed. Latency matters; alignment and variant calling read and write large files repeatedly.
• Warm storage (recent results): standard HDD or object storage for completed results within the clinical retention window. Accessible for result retrieval, report reissue, and reclassification workflows.
• Cold storage (long-term archive): compressed archive storage for samples past the active retrieval window. FASTQ is the typical archival format since BAM can be regenerated. Retention varies (CAP requires 2 years minimum for most NGS results) but many institutions retain indefinitely given lifetime clinical relevance of germline data.

A rough storage estimate: at 50 WES cases per week, assuming FASTQ archival at ~10 GB per sample and VCF/report retention, expect 25 to 50 TB of new data per year.

A genomic data warehouse is the infrastructure component that transforms a clinical laboratory from a sample-processing operation into a learning institution. Every sample processed, every variant classified, every clinical decision made: captured, structured, and made queryable for future cases.

Without a data warehouse, each new case starts from scratch. With one, a laboratory builds institutional memory that compounds in value over time.

What a genomic data warehouse does

Architecture patterns

• Centralized: all variant data in a single instance. Simplifies global querying. Best when the lab operates as a single organizational unit.
• Hub-and-spoke: central warehouse coexists with departmental data marts (rare disease, oncology, PGx) each optimized for its use case but feeding into the common repository. Balances centralized oversight with departmental flexibility.
• Federated: multiple independent instances, each maintained by a different lab or institution, with controlled exchange. Used in consortia and multi-site programs where data sovereignty prevents centralization.

Infrastructure is not just a technical challenge. It is an operational one. As sample volumes grow, the bottleneck shifts from sequencing throughput to interpretive capacity. Labs that scale successfully are those that build infrastructure designed for production throughput from the beginning.

High-throughput pipeline automation

A clinical genomics lab at scale cannot rely on analysts manually triggering analysis runs, monitoring pipeline progress, and moving files between systems. Production infrastructure requires:

• Automated pipeline triggering: new samples detected and analysis started without manual intervention.
• Parallel processing: multiple samples running simultaneously across compute nodes.
• Automated QC gating: samples that fail quality thresholds flagged automatically before entering the interpretation queue.
• Result routing: completed analyses automatically routed to the appropriate clinical team with no manual handoff.

RBAC at scale

As lab teams grow, access control complexity grows with them. Production clinical infrastructure needs a formal RBAC model that maps to lab roles:

• Analysts: can view and annotate variants, cannot finalize or sign out reports.
• Clinical reviewers: can finalize variant classifications, cannot modify pipeline configurations.
• Directors: full access including pipeline configuration and system administration.
• External collaborators: read-only access to specific cases or datasets, governed by BAAs.

Turnaround time management

TAT is a key clinical genomics metric and a common focus of CAP inspection. Infrastructure directly affects TAT at every stage: insufficient compute capacity creates analysis queues that extend TAT, manual handoffs add hours per case, poorly designed variant filtering that leaves too many candidates for human review extends interpretation time, and report generation that requires manual formatting adds time that should be automated. Building TAT targets into infrastructure design from the start (and instrumenting the pipeline to measure time at each stage) is essential for labs that need to meet clinical commitments.